enGene Therapeutics Inc. (ENGN) Shareholder Equity
- 2026-07-31: Common Stock, Value, IssuedUSD $632.02M; Additional Paid in Capital, Common StockUSD $64.13M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.35M; Retained Earnings (Accumulated Deficit)USD $-464.51M.
- 2026-04-30: Common Stock, Value, IssuedUSD $632.00M; Additional Paid in Capital, Common StockUSD $56.33M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.14M; Retained Earnings (Accumulated Deficit)USD $-432.01M.
- 2026-01-31: Common Stock, Value, IssuedUSD $631.99M; Additional Paid in Capital, Common StockUSD $52.18M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-842.00K; Retained Earnings (Accumulated Deficit)USD $-401.78M.
- 2025-10-31: Common Stock, Value, IssuedUSD $513.28M; Additional Paid in Capital, Common StockUSD $27.35M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-888.00K; Retained Earnings (Accumulated Deficit)USD $-372.03M.
enGene Therapeutics Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | $632.02M | $64.13M | $-1.35M | $-464.51M | $230.29M | 3 month · $7.81M | (m) |
| 2026-04-30 | $632.00M | $56.33M | $-1.14M | $-432.01M | $255.17M | 3 month · $4.14M | (m) |
| 2026-01-31 | $631.99M | $52.18M | $-842.00K | $-401.78M | $281.55M | 3 month · $2.80M | 3 month · $411.00K |
| 2025-10-31 | $513.28M | $27.35M | $-888.00K | $-372.03M | $167.71M | 12 month · $9.65M | (m) |
| 2025-07-31 | $510.16M | $25.87M | $-1.21M | $-334.15M | $200.67M | 3 month · $2.58M | (m) |
| 2025-04-30 | $510.12M | $23.30M | $-969.00K | $-305.16M | $227.29M | 3 month · $2.65M | (m) |
| 2025-01-31 | $509.81M | $20.76M | $-1.27M | $-279.35M | $249.95M | 3 month · $1.81M | (m) |
| 2024-10-31 | $509.81M | $18.95M | $-1.42M | $-254.73M | $272.61M | 12 month · $5.32M | 12 month · $319.00K |
| 2024-07-31 | $453.48M | $17.30M | $-1.02M | $-239.43M | $230.33M | 3 month · $1.46M | (m) |
| 2024-04-30 | $453.40M | $15.86M | $-1.02M | $-225.28M | $242.97M | 3 month · $1.92M | (m) |
| 2024-01-31 | $259.37M | $14.33M | $-1.02M | $-210.30M | $62.38M | 3 month · $291.00K | 3 month · $319.00K |
| 2023-10-31 | $259.37M | $13.72M | $-1.02M | $-199.59M | $72.49M | 12 month · $3.45M | (m) |
| 2023-07-31 | (m) | (m) | (m) | (m) | $-93.92M | 3 month · $37.00K | (m) |
| 2023-04-30 | (m) | (m) | (m) | (m) | $-89.24M | 3 month · $39.00K | (m) |
| 2023-01-31 | (m) | (m) | (m) | (m) | $-84.01M | 3 month · $20.00K | (m) |
| 2022-10-31 | $16.39M | $7.68M | $-1.02M | $-99.67M | $-76.61M | 12 month · $116.00K | (m) |
| 2021-10-31 | (m) | (m) | (m) | (m) | $-53.44M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |